| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Research and development | - | 0 | 2,239 | 3,371 |
| General and administrative | 1,577 | 1,837 | 2,142 | 2,468 |
| Total costs and expenses | 1,577 | 1,837 | 4,381 | 5,839 |
| Loss from operations | -1,577 | -1,837 | -4,381 | -5,839 |
| Other income/(expenses), net | 45 | -63 | 106 | 120 |
| Gain on sale of assets, net | - | 110 | - | - |
| Change in fair value of warrant liability | - | 3,455 | - | - |
| Net loss | -1,532 | -5,245 | -4,275 | -5,719 |
| Unrealized gain on securities available-for-sale | - | 0 | 51 | 83 |
| Other comprehensive gain, net of tax | - | 0 | 51 | 83 |
| Deemed dividend relating to warrant exchange | -618 | - | - | - |
| Comprehensive loss | - | -5,245 | -4,224 | -5,636 |
| Net loss attributable to common shareholders | -2,150 | - | - | - |
| Net loss per share - basic | -0.4 | -1.03 | -0.85 | -0.02 |
| Net loss per share - diluted | -0.4 | -1.03 | -0.85 | -0.02 |
| Weighted average common shares outstanding - basic | 5,435,829 | 5,086,985 | 5,037,829 | 249,350,963 |
| Weighted average common shares outstanding - diluted | 5,435,829 | 5,086,985 | 5,037,829 | 249,350,963 |
Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc. (MTNB)